Estrogen receptor (ER) and progesterone receptor (PgR), by ligand- binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

International Journal of Cancer

Volumn 86, Issue 3, 2000, Pages 111-117

  Elledge, Richard M ^a,b   Green, Stephanie ^c   Pugh, Reginald ^d   Allred, D Craig ^a   Clark, Gary M ^a   Hill, Julian ^e   Ravdin, Peter ^f   Martino, Silvana ^g   Osborne, C Kent ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Breast Care Center   (United States)

^c SW Oncology Group Statistical Center ^*  (United States)

^d ALLEGHENY HEALTH NETWORK   (United States)

^e N Mississippi Hematol and Oncology   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN PS2; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; BINDING COMPETITION; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; STATISTICAL MODEL; SURVIVAL; UNITED STATES;

ANTINEOPLASTIC AGENTS, HORMONAL; BINDING, COMPETITIVE; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LOGISTIC MODELS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOUTHWESTERN UNITED STATES; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034688931     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000320)89:2<111::aid-ijc2>3.0.co;2-w     Document Type: Article

References (43)

1. ALLRED, D.C., BUSTAMANTE, M.A., DANIEL, CO., GASKILL, H.V. and CRUZ, A.B., JR., Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch. Surg., 125, 107-113 (1990).
2. ALLRED, D.C., HARVEY, J.M., BERARDO, M. and CLARK, G.M., Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol., 11, 155-168 (1998).
3. AMERICAN SOCIETY OF CLINICAL ONCOLOGY, Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. clin. Oncol., 14, 2843-2877 (1996).
4. ANDERSEN, J. and POULSEN, H.S., Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: correlation with clinical endocrine response. J. Steroid Biochem., 30, 337-339 (1988).
5. ANDERSEN, J. and POULSEN, H.S., Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer, 64, 1901-1908 (1989).
6. BARNES, D.M., HARRIS, W.H., SMITH, P., MILLIS, R.R. and RUBENS, R.D., Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Brit J. Cancer, 74, 1445-1451 (1996).
7. BERGER, U, MANSI, J.L., WILSON, P. and COOMBES, R.C., Detection of estrogen receptor in bone marrow from patients with metastatic breast cancer. J. clin. Oncol. 5, 1779-1782 (1987).
8. BEZWODA, W.R., ESSER, J.D., DANSEY, R., KESSEL, I., RAD, M.M. and LANGE, M., The value of estrogen and progesterone receptor level correlates with response to tamoxifen. Cancer, 68, 867-872 (1991).
9. BURTON, G.V., FLOWERS, J.L., COX, E.B., LEIGHT, G.S., DENT, G.A., GEISINGER, K.R., MCCARTY, K.S. and MCCARTY, K.S., JR., Estrogen receptor determination by monoclonal antibody in line needle aspiration breast cancer cytologies: a marker of hormone response. Breast Cancer Res. Treat., 10, 287-291 (1987).
10. CLARK, G.M., MCGUIRE, W.L., HUBAY, C.A., PEARSON, O.H. and MARSHALL, J.S., Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med., 309, 1343-1347 (1983).
11. COOMBES, R.C., POWLES, T.J., BERGER, U., WILSON, P., MCCLELLAND, R.A., GAZET, J.C., TROTT, P.A. and FORD, H.T., Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet, 2, 701-703 (1987).
12. DE LENA, M., MARZULLO, F., SIMONE, G., LABRIOLOA, A., TOMMASI, S., PETRONI, S. and PARADISO, A., Correlation between ERICA and DCC assay in hormone receptor assessment of human breast cancer. Oncology, 45, 308-312 (1988).
13. GASKELL, D.J., HAWKINS, R.A., SANGSTERI, K., CHETTY, U. and FORREST, A.P.M., Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet, 1, 1044-1046 (1989).
14. GASPARINI, G., POZZA, F., DITTADI, R., MELI, S., CAZZAVILLAN, S. and BEVILACQUA, P., Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer. J. Cancer Res. clin. Oncol., 118, 557-563 (1992).
15. GELBFISH, G.A., DAVIDSON, A.L., KOPEL, S., SCHREIBMAN, B., GELBFISH, J.S., DEGENSHEIN, G.A., HERZ, H.L. and CUNNINGHAM, J.N., Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann. Surf., 207, 75-79 (1988).
16. GOULDING, H., PINDER, S., CANNON, P., PEARSON, D., NICHOLSON, R., SNEAD, D., BELL, J., ELSTON, C.W., ROBERTSON, J.F., BLAMEY, R.W. and ELLIS, I.O., A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum. Pathol., 26, 291-294 (1995).
17. HARVEY, J.M., CLARK, G.M., OSBORNE, C.K. and ALLRED, D.C., Estrogen receptor status by immunohislochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. clin. Oncol., 17, 1474-1481 (1999).
18. HAWKINS, R.A., SANGSTER, K., TESDALE, A., LEVACK, P.A., ANDERSON, E.D.C., CHETTY, A.U. and FORREST, A.P.M., The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction to response to endocrine therapy. Brit. J. Cancer, 58, 77-80 (1988).
19. JONAT, W., MAASS, H. and STEGNER, H.E., Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res., 46 (Suppl.), 4296S-4298S (1986).
20. KUUKASJARVI, T., KONONEN, J., HELIN, H., HOLLI, K. and ISOLA, J., Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. clin. Oncol., 14, 2584-2589 (1996).
21. MANNI, A., ARAFAH, B. and PEARSON, O.H., Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer, 46, 2838-2842 (1980).
22. McCARTY, K.S.J., MILLER, L.S., COX, E.B., KONRATH, J. and MCCARTY, K.S.S., Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. lab. Med., 109, 716-721 (1985).
23. MCCLELLAND, R.A., BERGER, U., MILLER, L.S., POWLES, T.J., JENSEN, E.V. and COOMBES, R.C., Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res., 46 (Suppl.), 4241s-4243s (1986).
24. MCCLELLAND, R.A., FINLAY, P., WALKER, K.J., NICHOLSON, D., ROBERTSON, J.F., BLAMEY, R.W. and NICHOLSON, R.I., Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res., 50, 3545-3550 (1990).
25. MOLINO, A. and 15 OTHERS, Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res. Treat., 45, 241-249 (1997).
26. MULLER-HOLZNER, E., ZEIMET, A.G., DAXENBICHLER, G., MARTH, C., MULKER, L.C. and DAPUNT, O., Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases. Breast Cancer Res: Treat., 25, 47-55 (1993).
27. NICHOLSON, R.I., BOUZUBAR, N., WALKER, K.J., MCCLELLAND, R., DIXON, A.R., ROBERTSON, J.F., ELLIS, I.O. and BLAMEY, R.W., Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Europ. J. Cancer. 27, 908-913 (1991).
28. NOMURA, Y., MIURA, S., KOYAMA, H., ENOMOTO, K., KASUMI, F., YAMAMOTO, H., KIMURA, M., TOMINAGA, T., IINO, H., MORIMOTO, T. and TASHIRO, H., Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer, 69, 153-164 (1992).
29. OZZELLO, L., DE ROSE, C., HABIF, D.V. and LIPTON, R., Immunostaining of estrogen receptors in paraffin sections of breast cancers using anti-estrophilin monoclonal antibodies. In: R. Ceriani (ed.), Monoclonal antibodies in breast cancer, pp. 3-12, M. Hijhoff, Boston (1985).
30. PERTSCHUK, L.P., EISENBERG, K.B., CARTER, A.C. and FELDMAN, J.G., Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer, 55, 1513-1518 (1985).
31. PERTSCHUK, L.P., FELDMAN, J.G., EISENBERG, K.B., CARTER, A.C., THELMO, W.L., CRUZ, W.P., THORPE, S.M., CHRISTENSEN, J., RASMUSSEN, B.B., ROSE, C. and GREENE, G.L., Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Cancer, 62, 342-349 (1988).
32. PERTSCHUK, L.P., FELDMAN, J.G., KIM, Y.-D., BRAITHWAITE, L., SCHNEIDER, F., BRAVERMAN, A.S. and AXIOTIS, C., Estrogen receptor immunocytochemistry in paraffin embedded tissue with ERID5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol-based ligand-binding assays. Cancer, 77, 2514-2519 (1996).
33. PERTSCHUK, L.P., KIM, D.S., NAYER, K., FELDMAN, J.G., EISENBER, K.B., CARTER, A.C., RONG, Z.T., THELMO, W.L., FLEISHER, J. and GREENE, G.L., Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer, 66, 1663-1670 (1990).
34. RAVDIN, P.M., GREEN, S., MELINK DORR, R., MCQUIRE, W.L., FABIAN, C., PUGH, R.P., CARTER, R.D., RIVKIN, S.E., BORST, J.R., BELT, R.J., METCH, B. and OSBORNE, C.K., Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group Study. J. clin. Oncol., 10, 1284-1291 (1992).
35. REINER, A., NEUMEISTER, B., SPONA, J., REINER, G., SCHEMPER, M. and JAKESZ, R., Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res., 50, 7057-7061 (1990).
36. REINER, A., SPONA, J., REINER, G., SCHEMPER, M., KOLB, R., KWASNY, W., FÜGGER, R., JAKESZ, R. and HOLZNER, H., Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Amer. J. Pathol., 125, 443-449 (1986).
37. ROBERTSON, J.F.R., BATES, K., PEARSON, D., BLAMEY, R.W., and NICHOLSON, R.I., Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Brit. J. Cancer, 65, 727-730 (1992).
38. SEYMOUR, L., MEYER, K., ESSER, J., MACPHAIL, A.P., BEHR, A. and BEZWODA, W.R., Estimation of PR and ER by immunocytochemistry in breast cancer. Amer. J. clin. Pathol., 94 (Suppl. 1), S35-S40 (1990).
39. SKLAREW, R.J., BOOMER, S.C. and PERTSCHUK, L.P., Quantitative imaging of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. Cytometry, 11, 359-378 (1990).
40. STIERER, M., ROSEN, H., WEBER, R., HANAK, H., SPONA, J. and TÜCHLER, H., Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Ann. Surg., 218, 13-21 (1993).
41. STONELAKE, P.S., BAKER, P.G., GILLESPIE, W.M., DUNN, J.A., SPOONER, D., MORRISON, J.M., BUNDRED, N.J., OATES, G.D., LEE, M.J.R., NEOPTOLEMOS, J.P., CHAN, S.Y. and BAKER, P.R., Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Europ. J. Cancer, 30A, 5-11 (1994).
42. THORPE, S.M., ROSE, C., RASMUSSEN, B.B., MOURIDSEN, H.T., BAYER, T. and KEIDING, N. ON BEHALF OFTHE DANISH BREAST CANCER COOPERATIVE GROUP, Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res., 47, 6126-6133 (1987).
43. WILLIAMS, M.R., TODD, J.H., ELLIS, I.O., DOWLE, C.S., HAYBITTLE, J.L., ELSTON, C.W., NICHOLSON, R.I., GRIFFITHS, K. and BLAMEY, R.W., Oestrogen receptors in primary and advanced breast cancer. An eight year review of 704 cases. Brit. J. Cancer, 55, 67-73 (1987).